Skip to content

Startup & venture capital news

Xige Biotech closes Series A plus first tranche

China Life Equity backs organoid based drug development

By /

LinkedInX
Xige Biotech: Xige Biotech closes Series A plus first tranche

Shenzhen based Xige Biotech announced the first close of a Series A plus round worth several hundred million renminbi on 4 November 2026. China Life Equity led the financing. Xige develops drug candidates using patient derived organoid models and artificial intelligence to study disease biology and identify targets. The company is advancing programmes in metastatic solid tumours while expanding into cardiac and kidney disease. The capital will support clinical development, new pipelines and further work on its research platform. Two independent Chinese technology and investment publications reported the financing, while a direct company announcement was not located.

Keep reading

More Funding

All stories